Eli Lilly Faces Headwinds Amid Regulatory Delay and Legal Challenge

Eli Lilly's stock is encountering pressure from two significant fronts: a postponed regulatory decision for a key obesity drug candidate and new antitrust litigation in the United States. While the company's established weight-loss franchise continues to deliver robust commercial performance, these developments introduce uncertainty for investors.

A compounding pharmacy, Strive Specialties, initiated legal action against Eli Lilly and Novo Nordisk on January 14, 2026, filing a lawsuit in the U.S. District Court for the Western District of Texas. The complaint introduces fresh legal risk for the pharmaceutical giant.

Allegations and Company Responses

The plaintiff accuses the two companies of restricting access to compounded GLP‑1 medications through exclusive arrangements with major telehealth providers. According to the suit, these agreements prevented physicians on such platforms from prescribing customized formulations.

Furthermore, Strive Specialties claims Eli Lilly disparaged compounded drugs as unsafe and interfered with its business relationships involving payment processors and technology partners.

Both Eli Lilly and Novo Nordisk have forcefully rejected the accusations. Eli Lilly labeled the lawsuit as "factually and legally baseless," suggesting it is an attempt to deflect from the plaintiff's own conduct. Novo Nordisk similarly dismissed the claims as unfounded and vowed a vigorous legal defense.

FDA Decision on Oral Drug Pushed to 2026

Separately, the U.S. Food and Drug Administration (FDA) has extended its review timeline for Eli Lilly's oral weight-loss drug, orforglipron. Internal documents cited by Reuters indicate the agency has set a new target action date of April 10, 2026, a delay from an anticipated late-March decision.

Should investors sell immediately? Or is it worth buying Eli Lilly?

This shift occurs despite the drug having been granted a Commissioner's National Priority Voucher, a designation typically intended to shorten the review period to one or two months. Based on current FDA guidance, Eli Lilly now projects a potential approval in the second quarter of 2026.

Competitive and Market Implications

The delay offers a clear advantage to rival Novo Nordisk, whose oral Wegovy tablet launched earlier this month. The timing is particularly consequential as the U.S. Medicare program is set to broaden coverage for anti-obesity medications starting in April. Key ramifications include:

• Novo Nordisk will have an extended period to solidify its first-mover position in the oral obesity drug market.
• The initial phase of wider Medicare reimbursement will commence without orforglipron being available.
• The drug is considered patient-friendly due to a lack of strict dietary requirements.
• Analysts at Goldman Sachs project the total market for oral GLP‑1 therapies could reach approximately $22 billion in annual sales by 2030.

Core Business and Pipeline Show Strength

Despite these challenges, Eli Lilly's foundational GLP‑1 franchise remains a powerful financial engine. The tirzepatide-based products Mounjaro (for diabetes) and Zepbound (for obesity) collectively generated over $10 billion in revenue in the most recent quarter.

Supportive clinical data continues to emerge from the company's pipeline:
* Results from the TOGETHER-PsA trial demonstrated that Zepbound, used in combination with Taltz, offered superior efficacy for obese patients with psoriatic arthritis.
* Studies indicate orforglipron helped patients maintain weight loss after switching from injectable therapies.
* Eli Lilly also announced a $1 billion AI co-innovation laboratory with NVIDIA, aimed at reinventing the drug discovery process.

Strategic Moves and Lofty Valuation

In a strategic expansion of its immunology portfolio, Eli Lilly disclosed the acquisition of Ventyx Biosciences on January 7, 2026. The move is designed to enhance its offerings of oral therapies for inflammatory diseases and bolster its small-molecule pipeline.

The company's market valuation currently exceeds $1 trillion. Its shares trade at a price-to-earnings ratio of approximately 52, while its return on equity stands at 96.82%, significantly above industry averages. Investors will gain further insight into the resilience of the GLP‑1 business's commercial momentum when Eli Lilly releases its next quarterly results on February 4, 2026.